|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheville JC, Tindall D, Boelter C, Jenkins
R, Lohse CM, Pankratz VS, Sebo TJ, Davis B and Blute ML: Metastatic
prostate carcinoma to bone: Clinical and pathologic features
associated with cancer-specific survival. Cancer. 95:1028–1036.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zimmerman GA, McIntyre TM, Prescott SM and
Stafforini DM: The platelet-activating factor signaling system and
its regulators in syndromes of inflammation and thrombosis. Crit
Care Med. 30(Suppl): S294–S301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melnikova V and Bar-Eli M: Inflammation
and melanoma growth and metastasis: The role of platelet-activating
factor (PAF) and its receptor. Cancer Metastasis Rev. 26:359–371.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bussolati B, Biancone L, Cassoni P, Russo
S, Rola-Pleszczynski M, Montrucchio G and Camussi G: PAF produced
by human breast cancer cells promotes migration and proliferation
of tumor cells and neo-angiogenesis. Am J Pathol. 157:1713–1725.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fallani A, Calorini L, Mannini A,
Gabellieri S, Mugnai G and Ruggieri S: Platelet-activating factor
(PAF) is the effector of IFN gamma-stimulated invasiveness and
motility in a B16 melanoma line. Prostaglandins Other Lipid Mediat.
81:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Lan T, Zhang W, Dong L, Kang N,
Zhang S, Fu M, Liu B, Liu K, Zhang C, et al: Platelet-activating
factor receptor-mediated PI3K/AKT activation contributes to the
malignant development of esophageal squamous cell carcinoma.
Oncogene. 34:5114–5127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Y, Zhang M, Zhang X, Cai Q, Hong S,
Jiang W and Xu C: Synergistic effects of combined
platelet-activating factor receptor and epidermal growth factor
receptor targeting in ovarian cancer cells. J Hematol Oncol.
7:392014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giaginis C, Kourou E, Giagini A, Goutas N,
Patsouris E, Kouraklis G and Theocharis S: Platelet-activating
factor (PAF) receptor expression is associated with
histopathological stage and grade and patients' survival in gastric
adenocarcinoma. Neoplasma. 61:309–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Axelrad TW, Deo DD, Ottino P, Van Kirk J,
Bazan NG, Bazan HE and Hunt JD: Platelet-activating factor (PAF)
induces activation of matrix metalloproteinase 2 activity and
vascular endothelial cell invasion and migration. FASEB J.
18:568–570. 2004.PubMed/NCBI
|
|
11
|
Melnikova VO, Mourad-Zeidan AA, Lev DC and
Bar-Eli M: Platelet-activating factor mediates MMP-2 expression and
activation via phosphorylation of cAMP-response element-binding
protein and contributes to melanoma metastasis. J Biol Chem.
281:2911–2922. 2006. View Article : Google Scholar
|
|
12
|
Zhang L, Wang D, Jiang W, Edwards D, Qiu
W, Barroilhet LM, Rho JH, Jin L, Seethappan V, Vitonis A, et al:
Activated networking of platelet activating factor receptor and
FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk
ovarian epithelium. Reprod Biol Endocrinol. 8:742010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Y, Zhang X, Hong S, Zhang M, Cai Q,
Zhang M, Jiang W and Xu C: The expression of platelet-activating
factor receptor modulates the cisplatin sensitivity of ovarian
cancer cells: A novel target for combination therapy. Br J Cancer.
111:515–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Melnikova VO, Balasubramanian K, Villares
GJ, Dobroff AS, Zigler M, Wang H, Petersson F, Price JE, Schroit A,
Prieto VG, et al: Crosstalk between protease-activated receptor 1
and platelet-activating factor receptor regulates melanoma cell
adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.
J Biol Chem. 284:28845–28855. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hackler PC, Reuss S, Konger RL, Travers JB
and Sahu RP: Systemic platelet-activating factor receptor
activation augments experimental lung tumor growth and metastasis.
Cancer Growth Metastasis. 7:27–32. 2014.PubMed/NCBI
|
|
16
|
Kitagawa D, Taketomi A, Kayashima H,
Kuroda Y, Itoh S, Yamashita Y and Maehara Y: Expression of
platelet-activating factor receptor: A novel prognosticator in
patients with hepatocellular carcinoma following hepatectomy.
Oncology. 72:381–387. 2007. View Article : Google Scholar
|
|
17
|
Jan CR and Chao YY: Novel effect of
Y-24180, a presumed specific platelet activation factor receptor
antagonist, on Ca2+ levels and growth of human prostate
cancer cells. Cell Signal. 16:959–965. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Littlepage LE, Sternlicht MD, Rougier N,
Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI and Werb
Z: Matrix metalloproteinases contribute distinct roles in
neuroendocrine prostate carcinogenesis, metastasis, and
angiogenesis progression. Cancer Res. 70:2224–2234. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Slavin S, Yeh CR, Da J, Yu S, Miyamoto H,
Messing EM, Guancial E and Yeh S: Estrogen receptor α in
cancer-associated fibroblasts suppresses prostate cancer invasion
via modulation of thrombospondin 2 and matrix metalloproteinase 3.
Carcinogenesis. 35:1301–1309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu F, Liu P, Li J and Zhang Y: Eotaxin-1
promotes prostate cancer cell invasion via activation of the
CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep.
31:2049–2054. 2014.PubMed/NCBI
|
|
21
|
Yamashita CM, Radisky DC, Aschner Y and
Downey GP: The importance of matrix metalloproteinase-3 in
respiratory disorders. Expert Rev Respir Med. 8:411–421. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davies G, Jiang WG and Mason MD:
E-cadherin and associated molecules in the invasion and progression
of prostate cancer. Oncol Rep. 5:1567–1576. 1998.PubMed/NCBI
|
|
24
|
Khamis ZI, Iczkowski KA and Sang QX:
Metastasis suppressors in human benign prostate, intraepithelial
neoplasia, and invasive cancer: Their prospects as therapeutic
agents. Med Res Rev. 32:1026–1077. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
28
|
Sosa MS, Avivar-Valderas A, Bragado P, Wen
HC and Aguirre-Ghiso JA: ERK1/2 and p38α/β signaling in tumor cell
quiescence: opportunities to control dormant residual disease. Clin
Cancer Res. 17:5850–5857. 2011. View Article : Google Scholar : PubMed/NCBI
|
